Management of Symptomatic Vasospasm Following Subarachnoid Hemorrhage

Initial Management

The American Heart Association recommends induced hypertension to elevate systolic blood pressure while maintaining euvolemia in patients with symptomatic vasospasm following subarachnoid hemorrhage (SAH) 1, 2
Nimodipine administration is recommended for all patients with SAH, with a dose of 60 mg every 4 hours for 21 consecutive days, started within 96 hours of hemorrhage onset, as it has proven benefit for preventing delayed cerebral ischemia (DCI) and improving functional outcomes 1, 3

Maintaining euvolemia is crucial, as hypovolemia increases the risk of DCI 4, 1
Induced hypertension is recommended to improve cerebral perfusion in patients with symptomatic vasospasm, with the target systolic blood pressure determined by neurological response 1, 2, 5
Prophylactic hypervolemia, as part of triple-H therapy, is not recommended and may be harmful 1, 2, 6

Cerebral angioplasty may be reasonable for severe vasospasm in proximal large vessels to reverse cerebral vasospasm and reduce DCI progression 1, 2, 7
Intra-arterial vasodilator therapy may be considered for severe vasospasm, particularly for distal vessels not amenable to balloon angioplasty 1, 2, 7

Close monitoring of neurological status is essential for signs of improvement or deterioration 4, 1
Maintaining appropriate blood pressure monitoring during induced hypertension is crucial 1, 2
The treatment algorithm involves confirming symptomatic vasospasm, ensuring nimodipine therapy, optimizing volume status, initiating induced hypertension, and considering endovascular intervention if no improvement or deterioration occurs 1, 2, 4, 7